AbbVie (NYSE:ABBV) Reaches New 52-Week High – Here’s Why

AbbVie Inc. (NYSE:ABBV) shares reached a new 52-week high during trading on Wednesday . The stock traded as high as $268.41 and last traded at $266.4530, with a volume of 189319 shares traded. The stock had previously closed at $265.21.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Rinvoq received EU approval for children with juvenile arthritis. The European Commission approved Rinvoq (upadacitinib) for patients aged two and older with active polyarticular juvenile idiopathic arthritis who inadequately responded to, or could not tolerate, standard DMARD treatment. The approval adds a pediatric indication, an oral-solution formulation and Rinvoq’s 11th indication in the European Union. While the market opportunity is relatively small, the decision broadens the drug’s commercial reach and supports AbbVie’s effort to sustain Rinvoq growth. Approval was supported by the SELECT-YOUTH study and adult rheumatoid arthritis data. AbbVie Announces European Commission Approval of Rinvoq
• Positive Sentiment: AbbVie entered a multiyear AI drug-discovery collaboration with Iambic. The companies plan to use Iambic’s artificial-intelligence platform to identify and develop small-molecule therapies in immunology, neuroscience and oncology. The agreement could improve research efficiency and strengthen AbbVie’s longer-term pipeline, though it carries development risk and is unlikely to materially affect near-term earnings. AbbVie and Iambic Announce Collaboration
• Positive Sentiment: Allergan Aesthetics launched its AA Signature SKIN360 program in the U.S. The multimodal consultation and provider-education initiative is intended to support more comprehensive aesthetic treatments, potentially reinforcing AbbVie’s aesthetics franchise and patient engagement. Allergan Aesthetics Debuts AA Signature

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a research report on Tuesday, June 23rd. Morgan Stanley reiterated an “overweight” rating and set a $296.00 price target on shares of AbbVie in a research note on Monday, August 3rd. Royal Bank Of Canada raised their price objective on shares of AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research report on Friday, July 10th. Citigroup upped their target price on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th. Finally, HSBC increased their target price on shares of AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $276.64.

AbbVie Stock Performance

The stock’s fifty day moving average price is $256.31 and its 200-day moving average price is $232.58. The firm has a market cap of $469.55 billion, a PE ratio of 75.15, a P/E/G ratio of 1.19 and a beta of 0.29.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter in the previous year, the firm earned $2.97 earnings per share. The firm’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts forecast that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.6%. AbbVie’s payout ratio is currently 195.48%.

Insider Buying and Selling

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On AbbVie

Several institutional investors and hedge funds have recently made changes to their positions in the business. Burk Holdings LLC purchased a new position in AbbVie in the second quarter valued at approximately $30,000. Marquette Asset Management LLC lifted its holdings in shares of AbbVie by 52.2% in the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after buying an additional 48 shares in the last quarter. Abound Financial LLC bought a new position in AbbVie in the 4th quarter valued at $32,000. Principia Wealth Advisory LLC grew its position in AbbVie by 38.9% during the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock worth $40,000 after buying an additional 44 shares in the last quarter. Finally, Merkkuri Wealth Advisors LLC bought a new position in shares of AbbVie in the first quarter worth approximately $34,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.